Key Events This Week
30 Mar: Lower circuit hit amid heavy selling pressure
1 Apr: Upper circuit surge on robust buying interest
2 Apr: Consecutive upper circuit hit with strong momentum
3 Apr: Week closes at Rs.897.40 (+3.26%) outperforming Sensex
30 March 2026: Lower Circuit Hit Amid Heavy Selling Pressure
Venus Remedies Ltd opened sharply lower at Rs.843, down 2.29% from the previous close, and continued to decline throughout the session, touching an intraday low of Rs.819.65. The stock closed at Rs.825.60, down Rs.43.45 or 5.00%, triggering the lower circuit limit and halting further trading. This sharp fall was driven by intense selling pressure amid a broader sectoral downturn and investor concerns.
The Pharmaceuticals & Biotechnology sector itself declined by 1.19%, while the Sensex fell 2.29%, indicating that Venus Remedies underperformed both its sector and the broader market. The stock’s micro-cap status and liquidity constraints likely exacerbated the price volatility, with a total traded volume of 2,029 shares on the day.
Despite the steep decline, the stock remained above its medium- and long-term moving averages, suggesting that the recent weakness was short-term and possibly driven by panic selling rather than fundamental deterioration.
1 April 2026: Upper Circuit Surge Signals Renewed Buying Interest
Following the sharp decline, Venus Remedies Ltd rebounded strongly on 1 April, surging to its upper circuit price limit of Rs.861.05, a gain of 5.0% from the previous close. The stock opened with a gap-up of 4.38% and maintained robust buying momentum throughout the session, closing at the circuit limit and triggering a regulatory freeze on further price appreciation.
This rebound came despite the stock marginally underperforming its sector, which gained 1.60%, and the Sensex, which rose 1.97%. The total traded volume increased significantly to 7,572 shares, reflecting renewed investor interest. The stock’s technical position improved, remaining above all key moving averages except the 5-day average, indicating a medium-term uptrend with short-term consolidation.
The upper circuit hit suggested strong demand outstripping supply, reversing the prior two-day losing streak and signalling a potential shift in market sentiment.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
2 April 2026: Consecutive Upper Circuit Hit on Strong Momentum
Venus Remedies Ltd continued its upward trajectory on 2 April, hitting the upper circuit limit again with a 4.50% gain to close at Rs.897.40. The stock traded in a volatile range between Rs.831.10 and Rs.904.10, with a total volume of 16,603 shares and turnover of approximately Rs.3.84 crore. The regulatory freeze at the 5% upper circuit prevented further price gains during the session.
Notably, the stock outperformed its Pharmaceuticals & Biotechnology sector peers, which declined 1.24%, and the Sensex, which fell 0.67%, underscoring Venus Remedies’ relative strength amid a subdued market environment. The stock’s technical indicators were robust, trading above all major moving averages including the 5-day, signalling sustained bullish momentum.
However, delivery volumes declined by 36.47% compared to the five-day average, suggesting that much of the buying may have been driven by short-term traders rather than long-term holders. The stock’s proximity to its 52-week high of Rs.944.75, just 4.95% away, adds a technical milestone to watch in coming sessions.
Want to dive deeper on Venus Remedies Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Daily Price Performance: Venus Remedies Ltd vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-30 | Rs.825.60 | -5.00% | 32,182.38 | -2.29% |
| 2026-04-01 | Rs.865.10 | +4.78% | 32,814.97 | +1.97% |
| 2026-04-02 | Rs.897.40 | +3.73% | 32,839.65 | +0.08% |
Key Takeaways from the Week
Positive Signals: Venus Remedies demonstrated strong resilience and momentum by recovering swiftly from a lower circuit hit to achieve two consecutive upper circuit surges. The stock outperformed the Sensex by 3.55 percentage points over the week, closing at Rs.897.40. Technical indicators remain favourable with prices above all major moving averages, and the Mojo Score of 74.0 with a Buy grade supports a constructive medium-term outlook.
Cautionary Notes: The initial sharp decline and circuit hit on 30 March highlight the stock’s vulnerability to volatility and liquidity constraints typical of micro-cap stocks. Delivery volumes declined during the rally, suggesting speculative trading rather than sustained long-term accumulation. The stock remains close to its 52-week high, which may act as a resistance level in the near term. Investors should monitor volume trends and sector developments closely.
Conclusion
Venus Remedies Ltd’s week was characterised by significant price swings, reflecting a dynamic interplay of selling pressure and renewed buying enthusiasm. The stock’s ability to rebound from a lower circuit hit and register consecutive upper circuit gains amid a mixed sector and market environment underscores its underlying strength and investor interest. While the technical and fundamental indicators remain positive, the micro-cap nature and recent volatility warrant cautious monitoring. The coming sessions will be critical to assess whether the momentum can be sustained beyond the regulatory price band freezes and speculative trading activity.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
